financetom
Business
financetom
/
Business
/
Conagra Brands Fiscal Q4 Adjusted Earnings, Net Sales Decline; Issues Fiscal 2025 Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Conagra Brands Fiscal Q4 Adjusted Earnings, Net Sales Decline; Issues Fiscal 2025 Outlook
Jul 11, 2024 6:09 AM

08:08 AM EDT, 07/11/2024 (MT Newswires) -- Conagra Brands ( CAG ) reported fiscal Q4 adjusted earnings Thursday of $0.61 per diluted share, down from $0.62 a year earlier.

Analysts polled by Capital IQ expected $0.57.

Net sales for the quarter ended May 26 were $2.91 billion, compared with $2.97 billion a year earlier.

Analysts surveyed by Capital IQ expected $2.93 billion.

For fiscal 2025, the company expects adjusted earnings of $2.60 to $2.65 and organic net sales growth to range from a 1.5% decline to flat. Analysts surveyed by Capital IQ expect earnings of $2.69.

The company maintained a quarterly dividend at $0.35 per share to be paid Aug. 29 to stockholders of record Aug. 1.

Price: 28.23, Change: -0.58, Percent Change: -2.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
High Tide to Expand in European Cannabis Market in Early 2025
High Tide to Expand in European Cannabis Market in Early 2025
Dec 30, 2024
07:10 AM EST, 12/30/2024 (MT Newswires) -- High Tide (Nasdaq and TSXV: HITI) on Monday said it will expand further in the European cannabis market early next year after its recent rollout of the Cabana Club membership program in the U.S. and Europe showed encouraging results. The Cabana Club continues to be our crown jewel, now boasting over 1.55 million...
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
Dec 30, 2024
07:12 AM EST, 12/30/2024 (MT Newswires) -- Novartis ( NVS ) said in a regulatory filing Monday that its phase 3 study evaluating its one-time gene therapy intrathecal onasemnogene abeparvovec, or OAV101 IT, met its primary endpoint. Based on the results, there was an increase from baseline in the Hammersmith Functional Motor Scale - Expanded, or HFMSE, total score in...
AutoCanada Closes Second Credit Facility Amendment
AutoCanada Closes Second Credit Facility Amendment
Dec 30, 2024
07:11 AM EST, 12/30/2024 (MT Newswires) -- AutoCanada ( AOCIF ) on Monday said it has closed a second amendment to its credit facility with Scotiabank (BNS.TO) and other lenders. Key terms include lender approval to amend the definition of EBITDA to include add-backs of up to $35 million for specific one-time expenses, including US$20 million provisioned for Federal Trade...
BRIEF-Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
BRIEF-Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
Dec 30, 2024
Dec 30 (Reuters) - Marinus Pharmaceuticals ( MRNS ): * IMMEDICA TO ACQUIRE BIOPHARMACEUTICAL COMPANY MARINUS PHARMACEUTICALS, INC. * MARINUS PHARMACEUTICALS INC ( MRNS ) - IMMEDICA TO ACQUIRE MARINUS FOR $0.55 PER SHARE Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved